Immuneering (IMRX) Accounts Payables: 2020-2024
Historic Accounts Payables for Immuneering (IMRX) over the last 4 years, with Sep 2024 value amounting to $1.9 million.
- Immuneering's Accounts Payables rose 0.09% to $1.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.9 million, marking a year-over-year increase of 0.09%. This contributed to the annual value of $2.1 million for FY2023, which is 33.06% down from last year.
- According to the latest figures from Q3 2024, Immuneering's Accounts Payables is $1.9 million, which was down 25.91% from $2.6 million recorded in Q2 2024.
- In the past 5 years, Immuneering's Accounts Payables registered a high of $3.2 million during Q4 2022, and its lowest value of $1.2 million during Q2 2022.
- Moreover, its 3-year median value for Accounts Payables was $2.3 million (2024), whereas its average is $2.2 million.
- Per our database at Business Quant, Immuneering's Accounts Payables soared by 126.24% in 2022 and then crashed by 33.06% in 2023.
- Immuneering's Accounts Payables (Quarterly) stood at $1.5 million in 2020, then dropped by 5.82% to $1.4 million in 2021, then surged by 126.24% to $3.2 million in 2022, then tumbled by 33.06% to $2.1 million in 2023, then rose by 0.09% to $1.9 million in 2024.
- Its last three reported values are $1.9 million in Q3 2024, $2.6 million for Q2 2024, and $2.3 million during Q1 2024.